Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at The Goldman Sachs Group
Investment analysts at The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $37.00 price target on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 69.72% from […]
Investment analysts at The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $37.00 price target on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 69.72% from […]
